Research To Prevent Blindness

A drug that targets multiple pathogenic steps in diabetic retinopathy may be an ideal therapeutic strategy for the disease, Vanderbilt researchers report. Read More

Vanderbilt Eye Institute researchers have discovered that an imbalance in the ionic environment of retinal ganglion cells may contribute to functional impairments in glaucoma. Read More

David Calkins, PhD, vice chair and director of Research at the Vanderbilt Eye Institute, has been granted one of the preeminent awards in vision research — the Research to Prevent Blindness (RPB) Stein Innovation Award. Read More

Research to Prevent Blindness (RPB) has awarded two grants to faculty in the Department of Ophthalmology. Read More

The Vanderbilt Eye Institute recently received a grant for $115,000 from Research to Prevent Blindness, placing the total award amount for unrestricted grants from the organization at $860,000. Read More

Understanding how the protein TRPV1 helps neurons survive after glaucoma-related stressors could lead to new therapeutic strategies for glaucoma and other neurodegenerative conditions. Read More

A person’s mitochondrial gene “signature” could predict risk for diabetic retinopathy and guide early intervention strategies. Read More

Understanding the cellular and molecular responses of the eye to blast injury could guide new treatment development. Read More

An ion channel protein called TRIPV1 helps retinal neurons survive the elevated eye pressure associated with glaucoma. Read More

John Penn, Ph.D., vice chair of the Department of Ophthalmology and Visual Sciences at Vanderbilt, has been named to the Research to Prevent Blindness (RPB) Scientific Advisory Panel. Read More

A panel of metabolites – small molecules that are part of metabolic processes – that are unique to macular degeneration will shed light on the disease and aid diagnosis. Read More

Research to Prevent Blindness (RPB) recently awarded a $110,000 grant to Vanderbilt’s Department of Ophthalmology and Visual Sciences in support of research into the causes, treatment and prevention of blinding diseases. Read More

Glaucoma-causing mutations in the gene for myocilin reduce secretion of the protein into the aqueous humor, suggesting a new option for treatment. Read More

David Calkins, Ph.D., vice chair and director of Research for the Vanderbilt Eye Institute, was recently awarded a Research to Prevent Blindness (RPB) Senior Scientific Investigator Award. Read More

Research to Prevent Blindness has awarded a grant of $100,000 to Vanderbilt’s Department of Ophthalmology and Visual Sciences to support research into the causes, treatment and prevention of blinding diseases. Read More

Researchers have identified a new candidate gene for the most common form of glaucoma, which runs in families. The findings offer novel insights into glaucoma pathology and could lead to targeted treatment strategies. Read More